The estimated Net Worth of Jason Ehrlich is at least $10.3 Million dollars as of 14 June 2023. Mr. Ehrlich owns over 5,494 units of Kodiak Sciences Inc stock worth over $158,530 and over the last 5 years he sold KOD stock worth over $2,389,132. In addition, he makes $7,716,160 as Chief Medical Officer and Chief Development Officer at Kodiak Sciences Inc.
Jason has made over 39 trades of the Kodiak Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,494 units of KOD stock worth $13,570 on 14 June 2023.
The largest trade he's ever made was exercising 30,000 units of Kodiak Sciences Inc stock on 18 December 2019 worth over $74,100. On average, Jason trades about 6,830 units every 28 days since 2019. As of 14 June 2023 he still owns at least 64,182 units of Kodiak Sciences Inc stock.
You can see the complete history of Mr. Ehrlich stock trades at the bottom of the page.
Jason Ehrlich, M.D., Ph.D. is Chief Medical Officer and Chief Development Officer of the company since September 2018. Dr. Ehrlich, joined Kodiak as our Chief Medical Officer and Chief Development Officer in September 2018. Dr. Ehrlich, an ophthalmologist, is passionate about improving outcomes for patients with vision-threatening eye diseases through the development of innovative medicines. He is internationally recognized for his leadership and expertise in ophthalmic drug development. Prior to joining Kodiak, Dr. Ehrlich served in an executive capacity as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group of pharmaceutical companies. In roles of increasing responsibility at Genentech and Roche from July 2008 to August 2018, Dr. Ehrlich’s efforts as lead clinician for Lucentis in diabetic eye disease resulted in a unanimous FDA Advisory Committee vote and the first-ever FDA approval of an intraocular drug for diabetic macular edema; he then championed further expanding the Lucentis labeling into all forms of diabetic retinopathy, resulting in another first-ever FDA approval. Dr. Ehrlich guided the integration of the ophthalmic drug delivery company ForSIGHT VISION4 into Genentech/Roche after its acquisition, including oversight of the successful Phase II study of the ranibizumab Port Delivery System. In his work, Dr. Ehrlich has participated in or overseen numerous supplemental biologics license applications and both FDA and European health authority interactions. He led the global development of lampalizumab, including design and execution of the pivotal Phase III program that included over 1,800 patients, over 275 sites, and more than 20 countries. He also oversaw his team’s effort to secure FDA approvals of Lucentis in its prefilled syringe and for choroidal neovascularization due to pathologic myopia, and the successful transition to global Phase III development of RO6867461, a novel bispecific antibody for retinal vascular disease.
As the Chief Medical Officer and Chief Development Officer of Kodiak Sciences Inc, the total compensation of Jason Ehrlich at Kodiak Sciences Inc is $7,716,160. There are 1 executives at Kodiak Sciences Inc getting paid more, with Victor Perlroth having the highest compensation of $17,642,000.
Jason Ehrlich is 44, he's been the Chief Medical Officer and Chief Development Officer of Kodiak Sciences Inc since 2018. There are 12 older and no younger executives at Kodiak Sciences Inc. The oldest executive at Kodiak Sciences Inc is Robert Profusek, 70, who is the Lead Independent Director.
Over the last 6 years, insiders at Kodiak Sciences Inc have traded over $15,919,920 worth of Kodiak Sciences Inc stock and bought 10,439,459 units worth $472,964,631 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bros. Advisors Lp667, L.P.B..., and Victor Perlroth. On average, Kodiak Sciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $393,170. The most recent stock trade was executed by John A. Borgeson on 15 June 2024, trading 5,494 units of KOD stock currently worth $13,570.
about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
Kodiak Sciences Inc executives and other stock owners filed with the SEC include: